Bioray Biotech Co

Bioray Biotech Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Bioray Biotech Co (7561.TWO) as of Oct 22, 2026 is 7.04 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -0.79 % — a change of -986.63% (higher).

EBIT/Assets

7.04 %

YoY

-986.63%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Bioray Biotech Co is 2025 7.04 % . Operating Income to Assets Ratio (EBIT/Assets) of Bioray Biotech Co was 2024 -0.79 % . It decreases by -986.63% higher compared to the previous year.

The Bioray Biotech Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
2.71 TWD
Jan 1, 2019
1.37 TWD
Jan 1, 2020
-0.05 TWD
Jan 1, 2021
-1.74 TWD
Jan 1, 2022
-0.04 TWD
Jan 1, 2023
-3.56 TWD
Jan 1, 2024
-0.79 TWD
Jan 1, 2025
7.04 TWD
The Bioray Biotech Co EBIT/Assets history
YEAREBIT/AssetsYoY
7.04 %-986.63%
-0.79 %-77.70%
-3.56 %+8,974.57%
-0.04 %-97.74%
-1.74 %+3,629.98%
-0.05 %-103.40%
1.37 %-49.50%
2.71 %-1,989.26%
-0.14 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioray Biotech Co Stock analysis

What does Bioray Biotech Co do? BioRay Biotech Co., Ltd. generates revenue through its biological health products, functional medical testing services, and cell storage and preparation offerings. The company sells personalized probiotics, anti-allergic and intestinal probiotics, diabetes probiotics, female urinary tract products, and anti-arthritis probiotics. Functional medical testing includes personalized bacteria, personalized fungi, intestinal normal bacteria, quantitative magnesium detection in red blood cells, metabolic gene polymorphism analysis, and lymphocyte grouping. Cell storage services feature stem cell storage, immune cell storage, and cytokine induced killer (CIK) immune cell preparations. The primary customers for these products and services are individuals seeking personalized health solutions, including those managing chronic conditions like diabetes or arthritis. The company targets health-conscious consumers and medical professionals requiring specialized testing and cell-based therapies. BioRay Biotech focuses on delivering tailored health and medical services through its integrated product and service portfolio. Revenue streams are derived from direct sales of health products, testing service fees, and cell storage contracts. The business model emphasizes customization, with each product and service segment catering to specific health needs. The company’s offerings are structured to address individual health challenges through scientific and personalized approaches. Bioray Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioray Biotech Co stock

Operating Income to Assets Ratio (EBIT/Assets) of Bioray Biotech Co is 7.04 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Bioray Biotech Co changed from -0.79 % to 7.04 %, representing a -986.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Bioray Biotech Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Bioray Biotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Bioray Biotech Co

All Key Metrics — Bioray Biotech Co